Streetbeat News

VINC

Vincerx Pharma, Inc.

Industry

Biotechnology

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Open

0.30

Mkt cap

9.9M

Volume

358K

High

0.31

P/E Ratio

-0.28

52-wk high

9.37

Low

0.29

Div yield

N/A

52-wk low

0.29

The article highlights the performance of 12 health care stocks during Thursday's after-market session. Vaxart (VXRT) saw the highest gain with a 146.7% increase, while Alzamend Neuro (ALZN) experienced the largest decline at 24.9%.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 8:31 pm

Vincerx Pharma (NASDAQ:VINC) reported Q1 EPS of $(0.58), missing the consensus estimate of $(0.29) by 100%. This represents a 14.71% improvement over the previous year's loss of $(0.68) per share.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:38 pm

Vincerx Pharma's shares are trading higher after the company announced a proposed underwritten public offering of common stock and warrants, reversing earlier losses.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:04 pm

Aon plc shares fell by 7.4% after reporting quarterly financial results below market expectations. Other stocks showed significant movement, with Biodexa Pharmaceuticals and Pineapple Energy among the top gainers, while iClick Interactive and Nuwellis were notable losers.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 5:56 pm

Vincerx Pharma Inc (NASDAQ:VINC) shares fell by 9.7% to $0.81 after announcing a public offering priced at $0.75 per share and accompanying warrant, aiming to raise approximately $16.5 million. The offering includes 6 million shares of common stock and pre-funded warrants for up to 16 million shares, with Leerink Partners as the sole bookrunning manager. The offering is expected to close around April 30. Year to date, VINC shares have lost 38.13%, outperforming its historical average annual return of -62.46%.

Portfolio Pulse from Henry Khederian

April 26, 2024 | 3:31 pm

Alphabet Inc. reported first-quarter revenue of $80.539 billion, a 15% increase year-over-year, surpassing estimates. Earnings were $1.89 per share, beating forecasts. Alphabet announced a $70 billion share repurchase program and its first-ever quarterly dividend, causing shares to rise 11.9% in pre-market trading. Other stocks also moved significantly in pre-market trading, with notable gainers including Tevogen Bio Holdings, Pineapple Energy, and Freight Technologies, and losers such as Aclarion, Vincerx Pharma, and SCWorx Corp.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 12:18 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings (TVGN) led the gainers with a 75.3% increase, while Processa Pharma (PCSA) experienced the largest drop among the losers, falling 15.6%. Other notable movers included Cryo-Cell International (CCEL) and Moleculin Biotech (MBRX) with substantial gains, and SCWorx (WORX) and Nuwellis (NUWE) with notable losses.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 12:06 pm

Vincerx Pharma's stock is trading lower following the announcement of a proposed underwritten public offering of common stock and warrants.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 12:05 pm

Vincerx Pharma, Inc. (NASDAQ:VINC) has announced the pricing for its underwritten public offering, which includes 6,000,000 shares of common stock and warrants, as well as pre-funded warrants for up to 16,000,000 shares. The offering prices are set at $0.75 for each share and accompanying warrant, and $0.7499 for each pre-funded warrant and accompanying warrant.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:29 am

In Thursday's after-market session, health care stocks saw significant movements. Tevogen Bio Holdings led the gainers with a 51.8% increase, while Vincerx Pharma experienced the largest drop among the losers, declining by 17.5%. ResMed and DexCom reported their Q3 and Q1 earnings, respectively, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 8:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.